Takeda Chemical Industries, Inc.

Tobira Therapeutics, Inc.

Takeda Pharmaceutical Company Limited

Mitsuru Shiraishi

Satoshi Yamamoto

Naoyuki Kanzaki

Masanori Baba

Yoshio Aramaki

Masaki Seto

Osamu Nishimura

Mitsuo Numata

Masayoshi Yamaoka

Shinji Terao

Isao Minamida

Toshio Miyawaki

Yuji Iizawa

Katsuji Aikawa

Susumu Tsushima

Michiyuki Sendai

Shoji Fukumoto

Tsuneo Oda

Susumu Honda

Toshifumi Watanabe

Takahito Kitayoshi

Kaneyoshi Kato

Tatsuo Nishimura

Hidekazu Sawada

Norichika Matsumoto

Ken-ichi Kuroshima

Keiji Kusumoto

Isuke Imada

Mitsuru Kawada

Yoshitaka Maki

Shigeyuki Takada

Masami Kusaka

Masafumi Misaki

Shohei Hashiguchi

Yasuko Ashida

Naoki Miyamoto

Tatsumi Matsumoto

Yoshio Imashiro

Isao Mimamida

Takahito Hara

Tsuyoshi Maekawa

Kohei Mishikawa

The present invention provides a new cyclic compound having a CCR antagonist activity, especially a CCR5 antagonist activity, and the use thereof. The compound of the present invention is represented by the formula: wherein, Ris a 5- to 6-membered ring group which may be substituted; Xis a bond or the like; ring A is a 5- to 6-membered ring group which may be substituted; ring B is a 8- to 10-membered ring group which may be substituted; Xis a bivalent group of 1 to 4 atom; Zis a bivalent cyclic ring group or the like; Zis a bond or the like; and Ris an amino group, a nitrogen-containing heterocyclic group which may be substituted or the like, or a salt thereof.

Bicyclic compound, production and use thereof

The present invention provides a new cyclic compound having a CCR antagonist activity, especially a CCR5 antagonist activity, and the use thereof. The compound of the present invention is represented by the formula: wherein, Ris a 5- to 6-membered ring group which may be substituted; Xis a bond or the like; ring A is a 5- to 6-membered ring group which may be substituted; ring B is a 8- to 10-membered ring group which may be substituted; Xis a bivalent group of 1 to 4 atoms; Zis a bivalent cyclic ring group or the like; Zis a bond or the like; and Ris an amino group, a nitrogen-containing heterocyclic group which may be substituted or the like, or a salt thereof.

The present invention provides a compound represented by the general formula: [wherein Ring A represents an optionally substituted 5- to 8-membered ring, Ring B represents a further optionally substituted 4- to 10-membered ring, Ring C represents a further optionally substituted benzene ring, Xrepresents carbon atom, Xrepresents a carbon atom, an oxygen atom, etc., W represents a nitrogen atom, etc., Yrepresents a group represented by the formula CRR(wherein Rrepresents a hydrogen atom, a cyano group, a nitro group, etc., and Rrepresents a hydrogen atom, a cyano group, a nitro group, etc., respectively), Yrepresents a group represented by the formula CRR(wherein Rrepresents a hydrogen atom, a cyano group, a nitro group, etc., and Rrepresents a hydrogen atom, a cyano group, a nitro group, etc., respectively), etc., and Rrepresents an electron-withdrawing group, respectively. The formularepresents a single bond or a double bond] or a salt thereof, which is useful as an androgen receptor modulator.

Fused benzene derivative and use

The present invention provides a compound represented by the formula: wherein Ris a 5- or 6-membered ring which may be substituted; The compound has excellent CCR5 antagonist activity and is useful as a prophylactic and/or therapeutic medicine for HIV infection in human peripheral mononuclear blood cells, especially AIDS.

Fused-ring pyridine derivative, process for producing the same, and use

The present invention provides a novel benzazepine derivative represented by formula: wherein, Ris a 5- or 6-membered aromatic ring, Ris lower alkyl group, etc., Y is an optionally substituted imino group, ring A and ring B are independently an optionally substituted aromatic ring, W is formula &#x2014;W&#x2014;X&#x2014;W&#x2014; (Wand Ware independently S(O)(m1 is 0, 1, or 2), etc., and Xis an optionally substituted alkylene group etc.), a preparation method and use thereof.

Benzazepine derivative, process for producing the same, and use

Compounds of the general formula (I):or salts thereof, which exhibit CCR5 antagonism and exert preventive and therapeutic effects against HIV infections: wherein Ris a 5- to 6-membered aromatic ring which bears a substituent represented by the general formula: R-Z-X-Z- (wherein Ris hydrogen or optionally substituted hydrocarbyl; X is optionally substituted alkylene; and Zand Zare each a heteroatom) and may be further substituted, with R being optionally bonded to the aromatic ring to form another ring; Y is optionally substituted imino; and Rand Rare each optionally substituted aliphatic hydrocarbyl or an optionally Substituted hetero-alicyclic group.

Benzazepine derivatives, process for the preparation of the same and uses thereof

Nasal preparation of guanidinoimino quinoline derivatives

Cyclic compounds and uses thereof

Anilide derivative, production and use thereof

Quaternary ammonium salts and their use

Aminoguanidine hydrazone derivatives, process for producing the same and drugs thereof

This invention is to provide a pharmaceutical composition for antagonizing CCR5 which comprises a compound of the formula:

Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative

Growing community of inventors

Amagasaki, Japan

Mitsuru Shiraishi